Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL202 + anti-tumor therapy in advanced solid tumors
NCT07169994Phase 2Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL202 in solid tumor (advanced stage), breast cancer, non-small cell lung cancer (NSCLC), sponsored by MediLink Therapeutics. Started Sep 2025; status: recruiting.
02
Drugs
YL202
03
Conditions
solid tumor (advanced stage)breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07169994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169994.